- $4.98m
- $12.43m
- $1.73m
Brief: VolitionRX Limited Awarded An Additional $1.4 Mln In Non-Dilutive Funding
Brief: VolitionRX Cash And Cash Equivalents As Of March 31 Totaled $16.2 Mln
Brief: Volitionrx Limited Executes A Contract For Clinical Trial Program In Lung Cancer
Brief: VolitionRX Ltd Signs Memorandum Of Understanding With Texas A&M University
Brief: Volitionrx Limited Extends Clinical Trial Program In Lung Cancer
Brief: Volitionrx Ltd Signs MOU With Fosun Long March In China
Brief: VolitionRx Cash And Cash Equivalents As Of Dec. 31, 2018 $13.4 Mln VS $10.1 Mln
Brief: Volitionrx Limited Q3 Loss Per Share $0.14
Brief: Volitionrx Ltd Files For Offering Of Up To 10.0 Million Shares Of Common Stock - SEC Filing
Brief: Volitionrx Ltd Files For Mixed Shelf Of Upto $100 Million
Brief: VolitionRx Limited Q2 Loss Per Share $0.15
Brief: VolitionRX Announces $9 Mln Private Placement
Brief: VolitionRX Limited Announces First Quarter 2018 Financial Results And Business Update
Brief: Volitionrx Signs A Global Sales And Distribution Agreement With Active Motif For Its New Ruo Kits
U.S. STOCKS ON THE MOVE-Autoweb, Spark Energy, Big Lots
VolitionRx: Worst day in 4-1/2 years on stock offering
Brief: Volitionrx Announces Proposed Underwritten Public Offering
Brief: Volitionrx Limited Announces Interim Results From 680-Subject Clinical Trial In Colorectal Cancer
Brief: VolitionRx limited announces third quarter results